During a live event, Ahmad Tarhini, MD, PhD, moderated a discussion on selection of immunotherapy regimens for patients with ...

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

Papaverine, an investigational drug shown to sensitise tumor cells to radiation therapy by blocking oxygen consumption in tumor cells in preclinical and ongoing clinical trials, is now being tested in ...

The FDA has granted clearance to the IND applications for both the therapeutic ( [ 225 Ac]Ac-AKY-1189) and imaging ( [ 64 ...

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...